SCHEMBL25434751

SCHEMBL25434751

NS(=O)(=O)c1cccc([N+](=O)[O-])c1NCC1CCCNC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
CYP19A1 P11511 1/20 0.37
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HTT P42858 1/20 0.35
ACHE P22303 1/20 0.34
DRD2 P14416 1/20 0.34
ADRA2C P18825 1/20 0.34
NPY1R P25929 1/20 0.34
NPY5R Q15761 1/20 0.34
BRD4 O60885 1/20 0.34
ATAD2 Q6PL18 1/20 0.34
CCNT1 O60563 1/20 0.34
ALOX15 P16050 2/20 0.34
CHEK1 O14757 2/20 0.34
GRM6 O15303 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4733973 0.87 KMT2A (0.45) KMT2AMEN1CYP19A1ALDH1A1LMNA
SCHEMBL2480616 0.80 KCNH2 (0.41) KMT2AMEN1ALDH1A1KDM4EHTT
SCHEMBL25173684 0.80 KCNH2 (0.41) KMT2AMEN1ALDH1A1KDM4EHTT
SCHEMBL25170416 0.80 KCNH2 (0.41) KMT2AMEN1ALDH1A1KDM4EHTT
SCHEMBL25176450 0.79 KMT2A (0.38) KMT2AMEN1CYP19A1ALDH1A1LMNA
SCHEMBL29903263 0.78 NSD2 (0.45) METAP2KMT2AMEN1ALDH1A1LMNA
SCHEMBL1700546 0.77 MAPT (0.52) KMT2AMEN1ALDH1A1LMNAHTT
SCHEMBL30802191 0.77 NPY5R (0.37) KMT2AMEN1CYP19A1ALDH1A1LMNA
SCHEMBL25176203 0.77 NPY5R (0.41) KMT2AMEN1CYP19A1ALDH1A1LMNA
SCHEMBL30313896 0.77 NPY5R (0.41) KMT2AMEN1CYP19A1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143532-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143532-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BCL2, BAX, BCL3 METAP2 978/4885KMT2A 3560/4885MEN1 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.